Principal Financial Group Inc. decreased its position in shares of Agilent Technologies Inc (NYSE:A) by 1.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 587,497 shares of the medical research company’s stock after selling 6,163 shares during the period. Principal Financial Group Inc. owned 0.18% of Agilent Technologies worth $39,632,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently bought and sold shares of the company. Captrust Financial Advisors lifted its position in Agilent Technologies by 2,121.1% during the fourth quarter. Captrust Financial Advisors now owns 422 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 403 shares during the last quarter. JOYN Advisors Inc. lifted its position in Agilent Technologies by 186.6% during the fourth quarter. JOYN Advisors Inc. now owns 470 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 306 shares during the last quarter. We Are One Seven LLC purchased a new stake in Agilent Technologies during the fourth quarter valued at approximately $33,000. Truehand Inc purchased a new position in shares of Agilent Technologies in the fourth quarter worth $33,000. Finally, Doyle Wealth Management purchased a new position in shares of Agilent Technologies in the fourth quarter worth $34,000.
A number of research analysts have issued reports on A shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $88.00 price target (up previously from $77.00) on shares of Agilent Technologies in a report on Monday, February 25th. Zacks Investment Research raised shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $88.00 price target for the company in a report on Friday, February 22nd. Janney Montgomery Scott reaffirmed a “buy” rating and issued a $90.00 price target (up previously from $80.00) on shares of Agilent Technologies in a report on Thursday, February 21st. Bank of America reaffirmed a “buy” rating and issued a $87.00 price target (up previously from $78.00) on shares of Agilent Technologies in a report on Thursday, February 21st. Finally, Deutsche Bank reaffirmed a “buy” rating and issued a $90.00 price target on shares of Agilent Technologies in a report on Thursday, February 21st. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $87.17.
Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, February 20th. The medical research company reported $0.76 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.03. The firm had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.27 billion. Agilent Technologies had a net margin of 22.86% and a return on equity of 19.90%. The business’s quarterly revenue was up 6.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.66 earnings per share. Equities analysts anticipate that Agilent Technologies Inc will post 3.06 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 24th. Stockholders of record on Tuesday, April 2nd will be paid a $0.164 dividend. The ex-dividend date is Monday, April 1st. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.82%. Agilent Technologies’s payout ratio is currently 23.66%.
In related news, VP Mark Doak sold 16,421 shares of the firm’s stock in a transaction on Friday, February 22nd. The shares were sold at an average price of $77.95, for a total transaction of $1,280,016.95. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Michael R. Mcmullen sold 17,491 shares of the firm’s stock in a transaction on Wednesday, January 30th. The shares were sold at an average price of $75.00, for a total transaction of $1,311,825.00. Following the sale, the chief executive officer now owns 456,430 shares in the company, valued at approximately $34,232,250. The disclosure for this sale can be found here. Insiders sold 83,722 shares of company stock worth $6,532,504 in the last quarter.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
See Also: What is the return on assets formula?
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.